Amendment to the Claims:

1. (Original) A compound represented by Formula A:

$$R_3$$
 R_4
 R_5
 R_7
 R_1
 R_8
 R_9
 R_1
 R_8
 R_9
 R_1

wherein:

n = 0, 1, 2 or 3 such that:

when n=0, the substituents R_{17} and R_{18} and the carbon atom to which they are bonded are not present; and

when n is 1, 2 or 3, the substituents R_{17} and R_{18} present on the respective carbon atom(s) may be the same or different and are independently selected from hydrogen or a substituent;

W is C or N, such that when W is N, R_4 is a lone pair of electrons;

Y is selected from N, O or S, such that:

when Y is O or S, R_1 is a lone pair of electrons; or when Y is N, R_1 is selected from hydrogen, unsubstituted or substituted C_{1-7} cycloalkyl, unsubstituted or substituted C_{1-7} cycloalkyl, unsubstituted or substituted C_{1-7} cycloalkyl- C_{1-7} alkyl, unsubstituted or substituted C_{5-20} aryl, unsubstituted or substituted or substituted or substituted or substituted C_{3-20} heterocyclyl, or a linking group to form a multimeric compound in which a plurality of compounds represented by Formula A are covalently bonded together;

independently R_2 and R_3 and/or R_4 and R_5 together can form an aromatic carbon or heterocyclic ring structure, optionally substituted with one or more aromatic substituents, or R_2 , R_3 , R_4 and R_5 are independently selected from an aromatic substituent;

 R_6 and R_7 are independently selected from hydrogen or independently or together can be a substituent;

 R_8 and R_9 are independently selected from hydrogen or independently or together can be a substituent;

wherein when R_{17} and R_{18} are present, they are independently selected from hydrogen or independently or together can be a substituent; and

one of the substituents R_6 and R_7 which is present on the carbon atom at the alpha position to the aromatic ring may form a double bond with one of the substituents R_8 and R_9 or R_{17} and R_{18} which is present on the carbon atom at the beta position to the aromatic ring; and

X is an anionic moiety;

and wherein:

the substituent or substituents are independently selected from halo, hydroxy, oxo, ether, formyl, C_{1-7} alkylacyl, C_{5-20} arylacyl, acylhalide, carboxy, ester, acyloxy, amido, acylamido, thioamido, tetrazolyl, amino, nitro, nitroso, azido, cyano, isocyano, cyanato, isocyanato, thiocyano, isothiocyano, sulfhydryl, thioether, sulfonic acid, sulfonate, sulfone, sulfonyloxy, sulfinyloxy, sulfamino, sulfonamino, sulfinamino, sulfamyl, sulfonamido, C_{1-7} alkyl, C_{1-7} haloalkyl, C_{1-7} hydroxyalkyl, C_{1-7} carboxyalkyl, C_{1-7} aminoalkyl, C_{5-20} aryl-

 C_{1-7} alkyl, C_{3-20} heterocyclyl, or C_{5-20} aryl; and

the aromatic substituent or substituents are independently selected from hydrogen, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -SH, -SMe, -SEt, -C(=0)Me, -C(=0)OH, -C(=0)OMe, -CONH₂, -CONHMe, -NH₂, -NMe₂, -NEt₂, -N(nPr)₂, -N(iPr)₂, -CN, -NO₂, -Me, -Et, -CF₃, -OCF₃, -CH₂OH, -CH₂CH₂OH, -CH₂NH₂, -CH₂CH₂NH₂, -Ph, ether, ester, amido, amino, C_{1-7} alkyl, C_{1-7} haloalkyl, C_{1-7} hydroxyalkyl, C_{1-7} carboxyalkyl, C_{1-7} aminoalkyl, or C_{5-20} aryl- C_{1-7} alkyl.

2. (Original) The compound according to claim 1, wherein the compound is represented by Formula Ai:

$$R_3$$
 R_4
 R_5
 R_7
 R_1
 R_9

wherein the substituents are as defined in claim 1.

3. (Currently amended) The compound according to claim 1 or claim 2, wherein the compound is represented by Formula Aii:

wherein the R_1 , R_6 , R_7 , R_8 and R_9 substituents are as defined in claim 1 and R_{10} , R_{11} , R_{12} , R_{13} , R_{14} , R_{15} and R_{16} substituents are independently selected an aromatic substituent.

- 4. (Currently amended) The compound according to any one of the preceding claims claim 1, wherein R_1 is a substituted C_{1-7} alkyl group selected from substituted C_{1-7} alkyl, C_{1-7} haloalkyl, C_{1-7} hydroxyalkyl, C_{1-7} carboxyalkyl, or C_{1-7} aminoalkyl.
- 5. (Currently amended) The compound according to any one of the preceding claims claim 1, wherein R_1 is a selected from C_{5-20} aryl, C_{5-20} carboaryl, C_{5-20} heteroaryl, C_{1-7} alkyl- C_{5-20} aryl or C_{5-20} haloaryl, optionally substituted with one or more substituents.
- 6. (Currently amended) The compounds according to any one of the preceding claims claim 1 which is:
- 1-(4-Methoxy-benzyl)-2,3-dihydro-1H-imidazo[1,2f]phenanthridinium bromide;
- 1-(2-Hydroxy-ethyl)-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylium bromide;
- 2,3-Dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylium bromide;
- 1-Isopropy1-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylium bromide;
- 1-Cyclopropyl-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylium bromide;
- 1-(4-Methoxy-phenyl)-2,3-dihydro-1H-imidazo[1,2f]phenanthridin-4-ylium bromide;
- 1-Phenyl-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylium bromide;
- 1-paramethoxyaniline-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-ylium bromide;

```
1-Methoxycarbonylmethyl-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridin-4-ylium bromide;
     1-(1-Methoxycarbonyl-2-phenyl-ethyl)-2,3-dihydro-1H-
imidazo[1,2-f]phenanthridin-4-ylium bromide;
     1-Benzyl-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-
ylium bromide;
     1-(2-Mercapto-ethyl)-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridin-4-ylium bromide;
     3-(4-Methoxy-benzyl)-2,3-dihydro-1H-imidazo[1,2-
a]quinolin-10-ylium bromide;
     1-(4-Methoxy-benzyl)-2,3-dihydro-1H-imidazo[2,1-
a]isoquinolin-4-ylium bromide;
     1-(4-Methoxy-benzyl)-2,3-dihydro-1H-imidazo[1,2-
a]pyridin-4-ylium bromide; 1-Propyl-2,3-dihydro-1H-
imidazo[1,2-f]phenanthridin-4-ylium bromide;
     1-(2-Hydroxy-1-methyl-ethyl)-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridin-4-ylium bromide;
     1-[1-(4-Methoxy-phenyl)-ethyl]-2,3-dihydro-1H-
imidazo[1,2-f]phenanthridin-4-ylium bromide;
     7-Bromo-1-(4-methoxy-benzyl)-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridin-4-ylium bromide;
     1-(4-Ethyl-phenyl)-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridin-4-ylium bromide;
     1-Hexy1-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-
ylium bromide;
     1-Dodecy1-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-
ylium bromide;
     1-Octadecy1-2,3-dihydro-1H-imidazo[1,2-f]phenanthridin-4-
ylium bromide;
     1-(3,3-Diphenyl-propyl)-2,3-dihydro-1H-imidazo[1,2-
f]phenanthridin-4-ylium bromide; or
     1-(4-Methoxy-benzyl)-2,3-dihydro-1H-imidazo[1,2-
```

7. (Original) A compound represented by Formula B:

c]quinazolin-4-ylium bromide.

$$R_3$$
 R_5
 R_5
 R_1
 R_7
 R_6

wherein:

n is 2 to 5;

R₁ is hydrogen;

independently R_2 and R_3 and/or R_4 and R_5 together can form an aromatic carbon or heterocyclic ring structure, optionally substituted with one or more aromatic substituents, or R_2 , R_3 , R_4 and R_5 are independently selected from an aromatic substituent;

 R_6 and R_7 are independently a substituent or a linking group to form a multimeric compound in which a plurality of compounds represented by Formula A as set out in any one of claims 1 to 7 and/or Formula B are covalently bonded together;

X is an anionic moiety;

and wherein:

the substituent or substituents are independently selected from halo, hydroxy, oxo, ether, formyl, C_{1-7} alkylacyl, C_{5-20} arylacyl, acylhalide, carboxy, ester, acyloxy, amido, acylamido, thioamido, tetrazolyl, amino, nitro, nitroso,

azido, cyano, isocyano, cyanato, isocyanato, thiocyano, isothiocyano, sulfhydryl, thioether, sulfonic acid, sulfonate, sulfone, sulfonyloxy, sulfinyloxy, sulfamino, sulfonamino, sulfinamino, sulfamyl, sulfonamido, C_{1-7} alkyl, C_{1-7} haloalkyl, C_{1-7} hydroxyalkyl, C_{1-7} carboxyalkyl, C_{1-7} aminoalkyl, C_{5-20} aryl- C_{1-7} alkyl, C_{3-20} heterocyclyl, or C_{5-20} aryl; and

the aromatic substituent or substituents are independently selected from hydrogen, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -SH, -SMe, -SEt, -C(=0)Me, -C(=0)OH, -C(=0)OMe, -CONH $_2$, -CONHMe, -NH $_2$, -NMe $_2$, -NEt $_2$, -N(nPr) $_2$, -N(iPr) $_2$, -CN, -NO $_2$, -Me, -Et, -CF $_3$, -OCF $_3$, -CH $_2$ OH, -CH $_2$ CH $_2$ OH, -CH $_2$ NH $_2$, -CH $_2$ CH $_2$ NH $_2$, -Ph, ether, ester, amido, amino, C $_{1-7}$ alkyl, C $_{1-7}$ haloalkyl, C $_{1-7}$ hydroxyalkyl, C $_{1-7}$ carboxyalkyl, C $_{1-7}$ aminoalkyl, or C $_{5-20}$ aryl-C $_{1-7}$ alkyl.

8. (Original) The compound according to claim 7 which is represented by Formula Bi:

wherein:

n is 2 to 5;

R₁ is hydrogen;

 R_6 and R_7 are independently hydrogen, a substituent or a linking group to form a multimeric compound in which a plurality of compounds represented by Formula A and/or Formula B are covalently bonded together;

 R_{10} , R_{11} , R_{12} , R_{13} , R_{14} , R_{15} and R_{16} are independently selected from hydrogen or an aromatic substituent; and

X⁻ is an anionic moiety and wherein:

the substituent or substituents are independently selected from halo, hydroxy, oxo, ether, formyl, C_{1-7} alkylacyl, C_{5-20} arylacyl, acylhalide, carboxy, ester, acyloxy, amido, acylamido, thioamido, tetrazolyl, amino, nitro, nitroso, azido, cyano, isocyano, cyanato, isocyanato, thiocyano, isothiocyano, sulfhydryl, thioether, sulfonic acid, sulfonate, sulfone, sulfonyloxy, sulfinyloxy, sulfamino, sulfonamino, sulfinamino, sulfamyl, sulfonamido, C_{1-7} alkyl, C_{1-7} haloalkyl, C_{1-7} hydroxyalkyl, C_{1-7} carboxyalkyl, C_{1-7} aminoalkyl, C_{5-20} aryl- C_{1-7} alkyl, C_{3-20} heterocyclyl, or C_{5-20} aryl; and

the aromatic substituent or substituents are independently selected from hydrogen, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -SH, -SMe, -SEt, -C(=0)Me, -C(=0)OH, -C(=0)OMe, -CONH₂, -CONHMe, -NH₂, -NMe₂, -NEt₂, -N(nPr)₂, -N(iPr)₂, -CN, -NO₂, -Me, -Et, -CF₃, -OCF₃, -CH₂OH, -CH₂CH₂OH, -CH₂NH₂, -CH₂CH₂NH₂, -Ph, ether, ester, amido, amino, C_{1-7} alkyl, C_{1-7} haloalkyl, C_{1-7} hydroxyalkyl, C_{1-7} carboxyalkyl, C_{1-7} aminoalkyl, or C_{5-20} aryl- C_{1-7} alkyl.

9. (Original) A compound which is represented by the Formula Bii:

wherein:

n is 2 to 5;

R₁ is hydrogen;

R₆ is hydrogen, a substituent; or a linking group to form a multimeric compound in which a plurality of compounds represented by Formula A and/or Formula B are covalently bonded together;

 R_{10} , R_{11} , R_{12} , R_{13} , R_{14} , R_{15} and R_{16} are independently selected from hydrogen or an aromatic substituent; and

X is an anionic moiety

and wherein:

the substituent or substituents are independently selected from halo, hydroxy, oxo, ether, formyl, C_{1-7} alkylacyl, C_{5-20} arylacyl, acylhalide, carboxy, ester, acyloxy, amido, acylamido, thioamido, tetrazolyl, amino, nitro, nitroso, azido, cyano, isocyano, cyanato, isocyanato, thiocyano,

isothiocyano, sulfhydryl, thioether, sulfonic acid, sulfonate, sulfone, sulfonyloxy, sulfinyloxy, sulfamino, sulfonamino, sulfinamino, sulfamyl, sulfonamido, C_{1-7} alkyl, C_{1-7} haloalkyl, C_{1-7} hydroxyalkyl, C_{1-7} carboxyalkyl, C_{1-7} aminoalkyl, C_{5-20} aryl- C_{1-7} alkyl, C_{3-20} heterocyclyl, or C_{5-20} aryl; and

the aromatic substituent or substituents are independently selected from hydrogen, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -SH, -SMe, -SEt, -C(=0)Me, -C(=0)OH, -C(=0)OMe, -CONH₂, -CONHMe, -NH₂, -NMe₂, -NEt₂, -N(nPr)₂, -N(iPr)₂, -CN, -NO₂, -Me, -Et, -CF₃, -OCF₃, -CH₂OH, -CH₂CH₂OH, -CH₂NH₂, -CH₂CH₂NH₂, -Ph, ether, ester, amido, amino, C_{1-7} alkyl, C_{1-7} haloalkyl, C_{1-7} hydroxyalkyl, C_{1-7} carboxyalkyl, C_{1-7} aminoalkyl, or C_{5-20} aryl- C_{1-7} alkyl.

- 10. (Currently amended) The compound according to any one of claims 7 to 9 claim 7, wherein n is 2 or 3.
- 11. (Currently amended) The compound according to any one of claims 7 to 10, which is::claim 7
 - 5-(2-tert-butylamino-ethyl)-phenanthridinium bromide;
 - 5-(2-Piperidin-1-yl-ethyl)-phenanthridinium bromide; piperazine phenanthridinium derivatives;

hydroxylamine derivatives;

- 1,5,9triaza-Cyclododecane;
- 5-[2-(4-methoxy-benzylsulfanyl)-ethyl]-phenanthridinium bromide.
- 12. (Currently amended) The compound according to any one of the preceding claims claim 1, wherein X the anionic moiety is selected from halogen, tosylate or mesylate.
- 13. (Currently amended) The compound according to any one of the preceding claims claim 1, wherein when the R_2 and R_3 and/or R_4 and R_5 substituents are present, one or both of these pairs of substituents together form an aromatic carbon or

heterocyclic ring structure, optionally substituted with one or more aromatic substituents.

- 14. (Currently amended) The compound according to any one of the preceding claims claim 1, wherein the compounds forming the multimeric compound are covalently bonded together via their respective R_1 substituents (Formula A) or via their R_6 or R_7 substituents (Formula B) or via a spacer group.
- 15. (Currently amended) A multimeric compound formed by covalently linking two or more of the same or different compounds according to any one of the preceding claimsclaim1.
- 16. (Currently amended) The multimeric compound according to claim 15, wherein compounds of Formula A are linked via the R_1 substituent—and/or compounds represented by Formula B are linked via the R_6 and/or R_7 substituents.
- 17. (Canceled)
- 18. (Currently amended) The multimeric compound according to any one of claims 15 to 17 claim 15, wherein the compounds are covalently bonded via a linker group or linker groups.
- 19. (Currently amended) The multimeric compound according to claim 18, wherein the linker groups is a C_{1-7} alk-di-yl group bonded to another group of Formula A or B in place of R_1 thereof; a piperazin-di-yl group bonded to another group of Formula A or B in place of R_1 thereof; a (N,N- C_{1-6} dialkylene) C_{1-7} alkylene amine bonded to two other groups of Formula A or B in place of R_1 thereof; or a cyclo (C_{4-8}) alk-tri-yl group bonded to two other groups of Formula A or B in place of R_3 thereof.
- 20. (Currently amended) The multimeric compound according to

any one of claims 15 to 17claim 15, wherein the multimeric compound is a dimer, trimer or tetramer of the compounds according to any one of claims 1 to 14.

- 21. (Currently amended) The multimeric compound according to any one of claims 13 to 18 claim 15, wherein the compounds of Formula A and/or B are covalently bonded to a spacer group.
- 22. (Currently amended) The multimeric compound according to claim 19 in which 2 or more, 3 or more, 4 or more, 5 or more, 10 or more, 20 or more, 50 or more, or 100 or more compounds represented by Formula A or B are covalently linked via one or more spacer groups.
- 23. (Currently amended) The multimeric compound according to claim 19 or claim 20, wherein the spacer group is a polyamine compound comprising an alkyl chain having a plurality of amine groups for reacting with the compounds of Formula A an/or B.
- 24. (Currently amended) The multimeric compound according to any one of claim 15 to 21 claim 15, wherein the compound is a selected from:

Dimers:

Ethylene diamine derivative with two groups of Formula A.

Hydroxylamine derivative with two groups of Formula B.

Piperazine derivative with two groups of Formula B.

DIP dimer derived from the spacer N1-(2-Amino-ethyl)-ethane1,2-diamine

DIP dimer derived from the spacer 2-Amino-1-[4-(2-amino-acetyl)-piperazin-1-yl]-ethanone

DIP dimer derived from the spacer 2-[4-(2-Amino-ethyl)-piperazin-1-yl]-ethylamine

Phenanthridinium dimer derived from the spacer 2-[4-(2-Amino-ethyl)-piperazin-1-yl]-ethylamine

Trimers:

Tris (2-aminoethylamine) derivatives with three groups of Formula A

Cis-triaminocyclohexane derivatives with three groups of Formula A.

2-Amino-1-[5,9-bis-(2-amino-acetyl)-1,5,9triaza-cyclododec-1-yl]-ethanone derivative with three groups of Formula A.

2-[5,9-Bis-(2-amino-ethyl)-1,5,9triaza-cyclododec-1-yl]ethylamine derivative with three groups of Formula A.

1,5,9-triaza-cyclododecane derivative with three groups of Formula B.

DIP trimer derived from the spacer 2-Amino-1-[5,9-bis-(2-amino-acetyl)-1,5,9triaza-cyclododec-1-yl]-ethanone

DIP trimer derived from the spacer Cyclohexane-1,3,5-triamine

Phenanthridinium trimer derived from the spacer 2-[5,9-Bis-(2-amino-ethyl)-1,5,9triaza-cyclododec-1-yl]-ethylamine

Tetramers:

Tetrakis-(6-amino-hexyl)-ammonium bromide derivative with four groups of Formula A.

- 25. (Currently amended) A composition comprising one or more compounds according to any one of the preceding claims claim 1.
- 26. (Canceled)
- 27. (Canceled)
- 28. (Currently amended) Use of a compound according to any one of claims 1 to 22 for the preparation of a medicamentA method for the treatment of a condition treatable by an anticancer agent, an anti-inflammatory agent, an antiprotozoal agent, or a topoisomerase inhibitorsaid method comprising administering to a patient in need of said treatment a therapeutically effective amount of a compound as claimed in claim 1.
- 29. (Currently amended) The usemethod according to claim 28, wherein the medicament compound is for the treatment of cancer.
- 30. (Canceled)
- 31. (Canceled)
- 32. (Original) A method of synthesising a heterocyclic aromatic cationic compound with an additional ring, the method comprising reacting a heterocyclic aromatic cationic compound comprising a ring nitrogen and at least one alpha hydrogen atom with a substituted or unsubstituted primary amine, a sulphate or a hydroxide, wherein the primary amine, sulphate or hydroxide reacts with the heterocylic aromatic compound by alpha addition, cyclisation and an oxidation step thereby providing the heterocyclic aromatic compound with an additional ring.
- 33. (Currently amended) The method according to claim 3032,

wherein the additional ring is a five membered ring.

- 34. (Currently amended) The method according to claim 30 or claim 3132, wherein the reaction is a one pot reaction.
- 35. (Currently amended) The method according to any one of claims 30 to 32 claim 32, wherein the method is for making a compound represented by Formula A as defined in claim 1 and comprises:

reacting a heterocyclic aromatic compound represented by the Formula A':

$$R_3$$
 W
 R_5
 W
 R_5
 R_7
 R_{17}
 R_8
 R_9
 R_1

wherein Y is a leaving group and n and the remaining substituents are as defined in claim 1;

with a primary amine represented by the formula:

$$R_b$$
 R_a NH_2

wherein the R_a -C- R_b substituents of the primary amine forms the group R_1 in the final compound;

the primary amine reacting with the phenanthridinium compounds of Formula A' by addition, cyclisation and oxidation to produce a compound represented by Formula A.

36. (Currently amended) The method according to any one of claims 30 to 33claim 32, wherein the method is for making a compound represented by Formula Ai or Aii as defined in claim 2 or claim 3 and comprises:

reacting a heterocyclic aromatic compound represented by the Formula Ai' or Aii' respectively:

$$R_3$$
 R_4
 R_5
 R_7
 R_8

$$\begin{array}{c|c} R_{14} \\ R_{15} \\ \hline R_{11} \\ \hline R_{10} \\ \hline R_{1$$

wherein Y is a leaving group and the remaining substituents are as defined in claim 2 or claim 3; with a primary amine represented by the formula:

$$R_b$$
 R_a NH_2

wherein the R_a -C- R_b substituents of the primary amine forms the group R_1 in the final compound;

the primary amine reacting with the phenanthridinium compounds of Formula Ai' by addition, cyclisation and oxidation to produce a compound represented by Formula Ai.

- 37. (Currently amended) The method according to any one of claims 30 to 34claim 32, wherein the method uses a primary amine which (1) has no substituents in the alpha position, or (2) has a primary carbon in the alpha position, or (3) has a secondary carbon in the alpha position), or (4) has a tertiary carbon in the alpha position, or (5) is or derives from an amino acid.
- 38. (Currently amended) The method according to any one of claims 30 to 34claim 32, wherein the primary amine is an aromatic amines, such as naphthalen-1-ylamine or anthracen-9-ylamine.
- 39. (Original) A method of making compounds represented by Formula B as defined in claim 7, the method comprising:

reacting a heterocyclic aromatic compound represented by the Formula B':

$$R_3$$
 R_5
 R_2
 R_1
 R_2
 R_1
 R_2
 R_1
 R_2
 R_3
 R_4
 R_5
 R_5
 R_1
 R_1
 R_2
 R_3
 R_4
 R_5
 R_5
 R_5
 R_1
 R_1

wherein Y is a leaving group and the remaining substituents are as defined in claim 7;

with a secondary amine represented by the Formula:

the secondary amine reacting with the compound of Formula B' to produce a compound represented by Formula B.

40. (Currently amended) The method according to claim 3739 for making compounds represented by Formula Bi as defined in claim 8, the method comprising:

reacting a heterocyclic aromatic compound represented by the Formula Bi':

wherein Y is a leaving group and the remaining substituents are as defined in claim 8;

with a secondary amine represented by the formula:

the secondary amine reacting with the compound of Formula Bi' by to produce a compound represented by Formula Bi.

41. (Original) A method of making compounds represented by Formula Bii as defined in claim 9, the method comprising:

reacting a heterocyclic aromatic compound represented by the Formula Bii':

with a sulphur containing compound such as substituted or unsubstituted thiol to produce a compound represented by Formula Bii.

42. (Currently amended) The method according to any one of claims 30 to 39claim 32, further comprising the step of forming a multimeric compound according to any one of claim 15 to 22.